Cytokine Release Syndrome

Cytokine release syndrome is the CAR-T safety problem discussed in E235｜20年内CAR-T治愈癌症？与刘诚博士聊聊癌症治疗的底层哲学. The episode describes it as excessive immune activation: engineered T cells recognize a target, become strongly activated, release large amounts of cytokines, and can create a dangerous systemic inflammatory response.

[[LiuCheng|刘诚]] says early CD19 [[CARTCellTherapy|CAR-T]] experience made cytokine storms a serious adoption bottleneck, including emergency-room treatment and early trial deaths in some cases. He argues that clinical handling has improved over the past several years, but that a deeper molecular design issue remains: recognition and activation are often tied together too tightly, like a steering wheel and accelerator welded together.

Key Claims

• CAR-T safety risk comes partly from the same immune activation that gives the therapy its power.
• Clinical management of cytokine storms has improved, but safety remains a scaling constraint.
• Liu argues that separating recognition from activation in CAR-T design could create a better brake system.
• The source also mentions ICANS as another CAR-T adverse reaction, but gives cytokine release syndrome the fuller explanation.

Connections

• CAR-T Cell Therapy, Ex Vivo CAR-T Manufacturing, and In Vivo CAR-T - therapy routes affected by safety limits.
• Cancer Immune Recognition Problem - immune activation must distinguish cancer from normal tissue without runaway response.
• Food and Drug Administration - U.S. approval and black-box-warning context named in the source.
• [[LiuCheng|刘诚]] - source explainer for the mechanism and molecular-design critique.